Literature DB >> 14975194

Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment.

Lakshmi Sastry1, Yi Xu, Ryan Cooper, Karen Pollok, Kenneth Cornetta.   

Abstract

To improve the purity of lentiviral vector supernatants for clinical studies we have evaluated plasmid DNA removal from lentiviral vectors and also the extent of plasmid DNA associated with transduced CD34 cells in an ex vivo transduction protocol. Optimal conditions of plasmid DNA removal by benzonase treatment were established by varying the temperature, time, and benzonase concentrations in the reaction mix and were determined to be 50 units of benzonase per milliliter of vector supernatant at 37 degrees C, for 15 min. No plasmid DNA was detected, suggesting efficient plasmid degradation was achieved under these experimental conditions. The infectious titer of benzonase-treated lentiviral vector (RRL-CMV-GFP) was nearly identical to the titer of untreated vector (2.3 +/- 0.3 x 10(6) transduction units per milliliter (TU/ml) and 2.7 +/- 0.3 x 10(6) TU/ml, respectively). Analysis of plasmid DNA in concentrated lentiviral vectors shows that concentration substantially decreases the amount of DNA per TU. Analysis of the extent of plasmid DNA associated with transduced CD34 cells in an ex vivo transduction protocol suggests that a minimal amount of plasmid is transferred to transduced cells if the vector supernatant was not previously treated with benzonase. In conclusion, benzonase treatment is effective in eliminating plasmid DNA from vector supernatants and treatment does not affect infectious titers. However, because there is minimal transfer of plasmid DNA to transduced cells under ex vivo transduction conditions, DNA removal from lentiviral vectors may not be essential for all ex vivo clinical applications.

Mesh:

Substances:

Year:  2004        PMID: 14975194     DOI: 10.1089/104303404772680029

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  28 in total

1.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  Using Pulmozyme DNase treatment in lentiviral vector production.

Authors:  Aaron Shaw; Daniela Bischof; Aparna Jasti; Aaron Ernstberger; Troy Hawkins; Kenneth Cornetta
Journal:  Hum Gene Ther Methods       Date:  2012-02       Impact factor: 2.396

3.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

4.  Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.

Authors:  Andreas Pichlmair; Sandra S Diebold; Stephen Gschmeissner; Yasuhiro Takeuchi; Yasuhiro Ikeda; Mary K Collins; Caetano Reis e Sousa
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

5.  Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.

Authors:  Victor G Kramer; Susan M Schader; Maureen Oliveira; Susan P Colby-Germinario; Daniel A Donahue; Diane N Singhroy; Randy Tressler; Richard D Sloan; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

6.  Measurement of human immunodeficiency virus type 1 preintegration transcription by using Rev-dependent Rev-CEM cells reveals a sizable transcribing DNA population comparable to that from proviral templates.

Authors:  Subashini R Iyer; Dongyang Yu; Angélique Biancotto; Leonid B Margolis; Yuntao Wu
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

7.  Efficient large volume lentiviral vector production using flow electroporation.

Authors:  Scott R Witting; Lin-Hong Li; Aparna Jasti; Cornell Allen; Kenneth Cornetta; James Brady; Rama Shivakumar; Madhusudan V Peshwa
Journal:  Hum Gene Ther       Date:  2011-10-24       Impact factor: 5.695

8.  Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef.

Authors:  Richard D Sloan; Björn D Kuhl; Daniel A Donahue; André Roland; Tamara Bar-Magen; Mark A Wainberg
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

9.  Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.

Authors:  Katherine T Marcucci; Julie K Jadlowsky; Wei-Ting Hwang; Megan Suhoski-Davis; Vanessa E Gonzalez; Irina Kulikovskaya; Minnal Gupta; Simon F Lacey; Gabriela Plesa; Anne Chew; J Joseph Melenhorst; Bruce L Levine; Carl H June
Journal:  Mol Ther       Date:  2017-10-20       Impact factor: 11.454

10.  Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes.

Authors:  Richard D Sloan; Daniel A Donahue; Björn D Kuhl; Tamara Bar-Magen; Mark A Wainberg
Journal:  Retrovirology       Date:  2010-05-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.